文献速递瓣膜病与结构性心脏病冠心病

主动脉瓣狭窄SAVR术后肾素-血管紧张素系统抑制治疗

Renin-angiotensin system inhibition after surgical aortic valve replacement for aortic stenosis.
PubMed 文献 · Heart · 2024-01-10

结果显示RAS抑制剂与MACE风险降低13%、全因死亡风险降低21%相关,ACEI与ARB均与较低MACE风险相关。

要点

  • SAVR术后使用RAS抑制剂与MACE风险降低13%相关。
  • 全因死亡风险降低21%是MACE获益的主要驱动因素。
  • 机械瓣亚组未见MACE获益,交互作用P=0.040。

核心结论

  • SAVR术后使用RAS抑制剂与MACE风险降低13%及全因死亡风险降低21%相关。
  • ACEI与ARB均与较低的MACE风险相关。

研究设计与样本

  • 平均年龄69.5岁,女性占40.4%,中位随访5.4(2.7-8.5)年。
  • 采用时间更新校正Cox回归模型比较使用与未使用RAS抑制剂的患者,并开展亚组分析及ACEI与ARB比较。

主要发现

  • 基线时53.6%患者被配发RAS抑制剂,该比例随访期间保持稳定。
  • RAS抑制剂与较低MACE风险相关(aHR 0.87,95%CI 0.81-0.93,p<0.001),主要由全因死亡风险降低驱动(aHR 0.79,95%CI 0.73-0.86,p<0.001)。
  • 除机械瓣亚组(aHR 1.07,95%CI 0.84-1.37,交互作用p=0.040)外,各亚组MACE风险降低一致。
  • ACEI治疗与较低MACE风险相关(aHR 0.89,95%CI 0.82-0.97),ARB亦相关(aHR 0.87,95%CI 0.81-0.93)。

临床怎么用

  • 对于SAVR术后无禁忌的患者,可考虑使用RAS抑制剂以降低MACE及全因死亡风险。
  • 机械瓣患者使用RAS抑制剂未见MACE获益,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The optimal medical therapy after surgical aortic valve replacement (SAVR) for aortic stenosis remains unknown. Renin-angiotensin system (RAS) inhibitors could potentially improve cardiac remodelling and clinical outcomes after SAVR. METHODS: All patients undergoing SAVR due to aortic stenosis in Sweden 2006-2020 and surviving 6 months after surgery were included. The primary outcome was major adverse cardiovascular events (MACEs; all-cause mortality, stroke or myocardial infarction). Secondary endpoints included the individual components of MACE and cardiovascular mortality. Time-updated adjusted Cox regression models were used to compare patients with and without RAS inhibitors. Subgroup analyses were performed, as well as a comparison between angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). RESULTS: A total of 11 894 patients (mean age, 69.5 years, 40.4% women) were included. Median follow-up time was 5.4 (2.7-8.5) years. At baseline, 53.6% of patients were dispensed RAS inhibitors, this proportion remained stable during follow-up. RAS inhibition was associated with a lower risk of MACE (adjusted hazard ratio (aHR) 0.87 (95% CI 0.81 to 0.93), p<0.001), mainly driven by a lower risk of all-cause death (aHR 0.79 (0.73 to 0.86), p<0.001). The lower MACE risk was consistent in all subgroups except for those with mechanical prostheses (aHR 1.07 (0.84 to 1.37), p for interaction=0.040). Both treatment with ACE inhibitors (aHR 0.89 (95% CI 0.82 to 0.97)) and ARBs (0.87 (0.81 to 0.93)) were associated with lower risk of MACE. CONCLUSION: The results of this study suggest that medical therapy with an RAS inhibitor after SAVR is associated with a 13% lower risk of MACE and a 21% lower risk of all-cause death.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Martinsson A, Törngren C, Nielsen SJ, et al. Renin-angiotensin system inhibition after surgical aortic valve replacement for aortic stenosis. Heart. 2024. PMID: 37460192. doi:10.1136/heartjnl-2023-322922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。